An engineered human IgG1 antibody with longer serum half-life.
about
Evolution of the immune system in humans from infancy to old ageFc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseasesFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsA perspective on the structure and receptor binding properties of immunoglobulin G FcUnraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based TherapeuticsStructural Insights into Neonatal Fc Receptor-based Recycling MechanismsAdvances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-lifeTargeting FcRn for the modulation of antibody dynamicsNeonatal Fc receptor and IgG-based therapeuticsThe neonatal Fc receptor, FcRn, as a target for drug delivery and therapySafety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy AdultsAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics.Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applicationsImpact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data.Next generation of antibody therapy for cancer.Geographical distribution of complement receptor type 1 variants and their associated disease risk.Tissues Expression, Polymorphisms Identification of FcRn Gene and Its Relationship with Serum Classical Swine Fever Virus Antibody Level in Pigs.Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities.Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate modelsEngineered monoclonal antibody with novel antigen-sweeping activity in vivo.Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domainClinical ramifications of the MHC family Fc receptor FcRn.Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometrySustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.Characterization and screening of IgG binding to the neonatal Fc receptor.Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-lifeA novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRnBalancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokineticsThe immunologic functions of the neonatal Fc receptor for IgGAntibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgGMolecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.Antibody therapeutics: isotype and glycoform selection.
P2860
Q26772107-09FDAF68-5AB9-4228-A9C8-69FC2D958A31Q26783175-48A9495D-EBF6-4D12-B23F-0468E9A1FA0EQ26822421-5E97835F-5D33-466E-A36C-E9C958AF2C0CQ26827579-743B32F5-E120-486A-8555-F926694F3064Q27027238-81292498-EA96-4259-97C7-3E302EF813E2Q27681475-A6E48075-868C-4159-9A30-34ECF5571971Q28079016-43A1CF26-B23C-4C4F-8948-385C7CAA98D7Q28080589-7151E1E5-582E-437F-83B0-07BB857D6E09Q28252134-4DF35DD5-1B38-4286-85A2-AD1E3C087739Q28257521-BD4466CE-0E3D-4F9C-B356-81D274701749Q28354370-8B3D9090-535B-4E39-A399-A69BAAA8A78BQ30275229-C3B71E89-4320-4BD7-84DE-6F753574B83BQ30566003-A32FCA2D-E983-4439-8048-0191CB9CAEC1Q30834514-FFF00D98-B369-4735-A01B-E08E5750E5F4Q31150455-FF328BE9-9DA9-4EAE-B634-5F4BAB01F0A3Q33579636-4FFF36D7-1029-4DCC-A662-528D34FF42F8Q33698822-79D5C990-4C13-46A3-A862-755CCADC24D0Q33884376-CACD0EAA-860F-4FE3-9730-541B4B70C882Q34055092-B74C2D90-C1FD-45F0-B5EE-78D0385B1E23Q34212762-14B24E21-6DDE-4A9E-9D60-6548741831BAQ34713889-207B1DE3-E39F-4161-A52D-4B35F35D8D01Q34718085-CC043812-7BF6-4EA7-89A6-718F74742BA3Q34724092-FA6AEFD8-AF5B-4A95-82A4-B4AF575F925CQ34754673-00E08111-EDAD-4BAB-89BC-E82328192261Q34884133-1C0B4ADA-B9AD-4D48-B4E6-88F485E9D325Q34982489-8B012C80-19A9-468C-A0DE-4ED3298165FAQ35163945-A67471AA-F55C-4583-B61E-2BD0E3F5F9C0Q35214746-04135043-B5B1-44FF-91CE-AC33675ADB59Q35612850-3B8D701C-672C-442B-BA4E-7B1FED83F9C8Q35929084-A4CC8373-55A8-43CB-929C-61B18FF0C8D8Q35952586-DF571567-B6D1-4281-AE57-3DDEB8B7CB73Q36080399-F01CA7C7-8FC8-4952-9C1E-67DACC017E76Q36211427-6082FE25-017F-42C3-9C93-679BD948528EQ36213182-ACBE6832-D3C9-4A8B-805E-DDF91E8CBE49Q36214076-DDFFC64F-C71A-47B2-99E9-193F5B61DA2AQ36214515-1B020BBF-C41F-4C26-8344-AB6D838976C0Q36542347-C71CF363-3116-48F1-B969-3DEF3F8AA266Q36759899-F5BE5123-0C9C-4AD6-9AFE-E8C253496AC3Q36767393-2C4A2EFB-EC33-499C-9882-C94FF628BDD4Q36922260-A2D793D5-90CD-4340-A0B5-8C22EF014BE2
P2860
An engineered human IgG1 antibody with longer serum half-life.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
An engineered human IgG1 antibody with longer serum half-life.
@en
An engineered human IgG1 antibody with longer serum half-life.
@nl
type
label
An engineered human IgG1 antibody with longer serum half-life.
@en
An engineered human IgG1 antibody with longer serum half-life.
@nl
prefLabel
An engineered human IgG1 antibody with longer serum half-life.
@en
An engineered human IgG1 antibody with longer serum half-life.
@nl
P2093
P1476
An engineered human IgG1 antibody with longer serum half-life.
@en
P2093
Joanna M Xiong
Mary G Johlfs
Meina Tao Tang
Naoya Tsurushita
Paul R Hinton
Stephen Keller
P304
P356
10.4049/JIMMUNOL.176.1.346
P407
P577
2006-01-01T00:00:00Z